Literature DB >> 33795837

Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations.

Laurent Kodjikian1,2, Mariacristina Parravano3, Andreas Clemens4,5, Rosa Dolz-Marco6, Frank G Holz7, Marion R Munk8, Massimo Nicolò9, Federico Ricci10, Rufino Silva11,12,13, S James Talks14, Rohini Kumar Verma4, Javier Zarranz-Ventura15,16, Sandrine A Zweifel17,18.   

Abstract

Current guidelines on the management of patients with neovascular age-related macular degeneration (nAMD) lack clear recommendations on the interpretation of fluid as seen on optical coherence tomography (OCT) imaging and the incorporation of this information into an ongoing disease treatment strategy. Our objective was to review current guidelines and scientific evidence on the role of fluid as a biomarker in the management of nAMD, and develop a clinically oriented, practical algorithm for diagnosis and management based on a consensus of expert European retinal specialists. PubMed was searched for articles published since 2006 relating to the role of fluid in nAMD. A total of 654 publications were screened for relevance and 66 publications were included for review. Of these, 14 were treatment guidelines, consensus statements and systematic reviews or meta-analyses, in which OCT was consistently recommended as an important tool in the initial diagnosis and ongoing management of nAMD. However, few guidelines distinguished between types of fluid when providing recommendations. A total of 52 publications reported primary evidence from clinical trials, studies, and chart reviews. Observations from these were sometimes inconsistent, but trends were observed with regard to features reported as being predictive of visual outcomes. Based on these findings, diagnostic recommendations and a treatment algorithm based on a treat-and-extend (T&E) regimen were developed. These provide guidance on the diagnosis of nAMD as well as a simple treatment pathway based on the T&E regimen, with treatment decisions made according to the observations of fluid as a critical biomarker for disease activity.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 33795837     DOI: 10.1038/s41433-021-01487-0

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  74 in total

1.  Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment.

Authors:  W Amoaku
Journal:  Eye (Lond)       Date:  2008-08-01       Impact factor: 3.775

2.  The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

Authors:  U Chakravarthy; M Williams
Journal:  Eye (Lond)       Date:  2013-10-25       Impact factor: 3.775

3.  Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity".

Authors:  Daniel Pauleikhoff; Bernd Kirchhof
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-05       Impact factor: 3.117

4.  Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN•OCT consensus.

Authors:  Giovanni Staurenghi; Srinivas Sadda; Usha Chakravarthy; Richard F Spaide
Journal:  Ophthalmology       Date:  2014-04-19       Impact factor: 12.079

5.  Evolving European guidance on the medical management of neovascular age related macular degeneration.

Authors:  U Chakravarthy; G Soubrane; F Bandello; V Chong; C Creuzot-Garcher; S A Dimitrakos; J-F Korobelnik; M Larsen; J Monés; D Pauleikhoff; C J Pournaras; G Staurenghi; G Virgili; S Wolf
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

Review 6.  Defining response to anti-VEGF therapies in neovascular AMD.

Authors:  W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang
Journal:  Eye (Lond)       Date:  2015-04-17       Impact factor: 3.775

7.  Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration.

Authors:  Ian A Rodrigues; Sara M Sprinkhuizen; Daniel Barthelmes; Mark Blumenkranz; Gemmy Cheung; Julia Haller; Robert Johnston; Ramasamy Kim; Caroline Klaver; Martin McKibbin; Nor Fariza Ngah; Suzann Pershing; Dato Shankar; Hiroshi Tamura; Adnan Tufail; Christina Y Weng; Inger Westborg; Catherine Yelf; Nagahisa Yoshimura; Mark C Gillies
Journal:  Am J Ophthalmol       Date:  2016-04-27       Impact factor: 5.258

8.  Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.

Authors:  Richard F Spaide; Glenn J Jaffe; David Sarraf; K Bailey Freund; Srinivas R Sadda; Giovanni Staurenghi; Nadia K Waheed; Usha Chakravarthy; Philip J Rosenfeld; Frank G Holz; Eric H Souied; Salomon Y Cohen; Giuseppe Querques; Kyoko Ohno-Matsui; David Boyer; Alain Gaudric; Barbara Blodi; Caroline R Baumal; Xiaoxin Li; Gabriel J Coscas; Alexander Brucker; Lawrence Singerman; Phil Luthert; Steffen Schmitz-Valckenberg; Ursula Schmidt-Erfurth; Hans E Grossniklaus; David J Wilson; Robyn Guymer; Lawrence A Yannuzzi; Emily Y Chew; Karl Csaky; Jordi M Monés; Daniel Pauleikhoff; Ramin Tadayoni; James Fujimoto
Journal:  Ophthalmology       Date:  2019-11-14       Impact factor: 12.079

Review 9.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Authors:  Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello
Journal:  Br J Ophthalmol       Date:  2014-09       Impact factor: 4.638

10.  Advances in Retinal Optical Imaging.

Authors:  Yanxiu Li; Xiaobo Xia; Yannis M Paulus
Journal:  Photonics       Date:  2018-04-27
View more
  4 in total

1.  Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.

Authors:  Varun Chaudhary; Frank G Holz; Sebastian Wolf; Edoardo Midena; Eric H Souied; Helmut Allmeier; George Lambrou; Tobias Machewitz; Paul Mitchell
Journal:  Ophthalmol Ther       Date:  2022-03-18

2.  A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study.

Authors:  F G Holz; Steffen Schmitz-Valckenberg; A Wolf; H Agostini; K Lorenz; A Pielen; N Feltgen; R Guthoff; C Quiering; A Clemens; K Jaeger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-21       Impact factor: 3.535

3.  A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea.

Authors:  Jae Hui Kim; Min Sagong; Se Joon Woo; Yu Cheol Kim; Heeyoon Cho; Young Hoon Lee; Iksoo Byon; Young Joon Jo; Hee Seung Chin; Youkyung Lee; Jae Eun Chae; Se Woong Kang
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

4.  Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan.

Authors:  Shigeru Honda; Yasuo Yanagi; Hideki Koizumi; Yirong Chen; Satoru Tanaka; Manami Arimoto; Kota Imai
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.